Published on : Feb 21, 2017
ALBANY, NY, Feb 21, 2017: The report is a comprehensive analysis of all the factors that are expected to influence the growth rate of the market and estimates the future scenario until 2022. According to the report, the opportunities in the Asia Pacific influenza therapeutics market will value US$1.71 bn by 2022, rising at a CAGR of 4.7% during the forecast period of 2016 to 2022.
The report observes that influenza, commonly referred as the flu, is typically an acute infection that is caused by three similar viruses, called influenza Type A, B, and C. The infection acts rapidly and has the potential for high mortality and morbidity, especially in the elderly patients and young children. As a result, prompt and effective treatment is necessary. Consequently, the report observes that prophylactic vaccination is usually preferred for seasonal influenza. The report also attributes the increasing demand in the Asia Pacific influenza therapeutics market to the changing perception of the patients for seasonal influenza vaccines. Asia Pacific resides several emerging economies such as India, China, Australia, and Japan wherein increased government initiatives is improving the healthcare infrastructure. These countries also have vast population base, which leads to substantial number of potential patients.
Click to get more details with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=950608
With continuous improvements in therapeutics to counter influenza over the years, cell culture vaccines are quickly replacing the traditional egg based manufacturing of seasonal influenza. Moreover, research and development of new formulations with further drive the uptake. Conversely, factors such as limited awareness of influenza’s threat, unpredictable vaccine demand, safety concerns, and decentralized vaccine policy and reimbursement system are expected to hinder the growth rate of the Asia Pacific influenza therapeutics market.
The report studies the treatment options available to the patients such as pharmacological treatments, non-pharmacological treatments, exercise, and dietary interventions. Several products have been analyzed in the report, including Fluarix Tetra by GlaxoSmithKline, FluQuadri, Vaxigrip, and Intanza/IDflu by Sanofi Pasteur, Agrippal, Fluad, Fluvax/Afluria, and Optaflu by CSL, Influvac by Abbott, GC Flu by Green Cross Corporation, SkyCellflu by SK Chemicals, and Nasovac-S by Serum Institute of India. Pipeline drugs analyzed for their development stage, molecule type, route of administration, and program type are VN-100 and MEDI3250 (VN-0107) by Daiichi Sankyo and ASP7374 (UMN-0502) by UMN Pharma.
The section of the report on clinical trial analysis explores overall failure rate as well as clinical trial duration and size. The report studies the treatment usage patterns, annual cost of therapy, and market size of country-wide markets for influenza therapeutics in India, China, Australia, South Korea, and Japan. The report also throws light on licensing deals, co-development deals, and the valuations of the deals.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org